Eicosapentaenoic acid ethyl ester: all 31 studies that test it
Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTNot yet recruitingNCT07762755Phase 4
- Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk Cardiovascular Disease.Not yet recruitingNCT06720662Not applicable
- Targeting Vascular INflammation in Patients With Community-Acquired PneumoniaRecruitingNCT06710080Phase 3
- Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the BodyTerminatedNCT05198843Phase 1/2Results posted
- PRevention Using EPA Against coloREctal CancerCompletedNCT04216251Phase 1/2Results posted
- The Effect of E-EPA on Circulating LDL and Plasma Lipid MetabolismCompletedNCT04152291Not applicableResults posted
- Vascepa to Accelerate Lipoprotein Uptake and EliminationCompletedNCT03885661Phase 1Results posted
- Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced CancerTerminatedNCT02940223Phase 2Results posted
- Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin TherapyCompletedNCT02926027Phase 4Results posted
- Brain Amyloid and Vascular Effects of Eicosapentaenoic AcidCompletedNCT02719327Phase 2/3Results posted
- Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic SubjectsTerminatedNCT02422446Phase 3Results posted
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on StatinCompletedNCT01492361Phase 3Results posted
- Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dLCompletedNCT01047683Phase 3Results posted
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)CompletedNCT01047501Phase 3Results posted
- IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssionActive, not recruitingNCT06466278Phase 2
- Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)WithdrawnNCT06280976Phase 4
- A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic AcidWithdrawnNCT04811404Phase 4
- The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular RiskCompletedNCT04562467Phase 4
- A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk AdultsTerminatedNCT04505098Phase 4
- PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention TrialCompletedNCT04460651Phase 3
- An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19CompletedNCT04412018Phase 2
- Efficacy of Ethyl Icosapentate in Patients With Severe HypertriglyceridemiaCompletedNCT04239950Phase 3
- OMega-3 Fatty Acid for the Immune Modulation of Colorectal CancerWithdrawnNCT03661047Phase 2
- EPA for Metastasis Trial 2Active, not recruitingNCT03428477Phase 3
- Eicosapentaenoic Acid Cerebral Vasospasm Therapy StudyCompletedNCT00839449Phase 4
- N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart FailureStatus unknownNCT00692718Phase 4
- Ethyl-EPA Treatment of Prodromal PatientsCompletedNCT00634361Phase 2/3
- Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and AntioxidantsCompletedNCT00419146Phase 2/3
- Protective Effect of EPA on Cardiovascular EventsCompletedNCT00231738Phase 4
- TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's DiseaseCompletedNCT00146211Phase 3
- Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major DepressionCompletedNCT00096798Phase 3